Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease

L. Bhatt, Deepak; Szarek, Michael; Pitt, Bertram; P. Cannon, Christopher; A. Leiter, Lawrence; K. McGuire, Darren; B. Lewis, Julia; C. Riddle, Matthew; E. Inzucchi, Silvio; Kosiborod, Mikhail; Z.I. Cherney, David; P. Dwyer, Jamie; M. Scirica, Benjamin; J. Bailey, Clifford; Díaz, Rafael; K. Ray, Kausik; A. Udell, Jacob; D. Lópes, Renato; Lapuerta, Pablo; Gabríel Steg, Philippe

doi:10.1056/nejmoa2030186

Public

Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease

Published in New England Journal of Medicine • Nov 16, 2020

Authors:

Deepak L. Bhatt

Michael Szarek

Bertram Pitt

Abstract

BACKGROUND: The efficacy and safety of sodium-glucose cotransporter 2 inhibitors such as sotagliflozin in preventing cardiovascular events in patients with diabetes with chronic kidney disease with or without albuminuria have not been well studied. METHODS: of body-surface area), and risks for cardi...

Subject

Diabetes mellitus

Medicine

Kidney disease

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!